Income Before Tax
Pre-Tax Income
Regeneron Pharmaceuticals Pre-Tax Income decreased by 20.4% to $831.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 8.2%, from $905.00M to $831.20M. Over 4 years (FY 2021 to FY 2025), Pre-Tax Income shows a downward trend with a -13.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionIncome Before Tax
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
Higher values indicate stronger overall profitability and operational efficiency before tax impacts.
Detailed definition
Measures the profitability of the company after all operating and non-operating expenses have been deducted, but before...
Peer comparison
A standard GAAP metric used universally to compare pre-tax performance across different industries.
Metric ID:
income_before_taxHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.75B | $1.82B | $2.50B | $1.06B | $963.20M | $1.51B | $1.32B | $858.00M | $1.08B | $1.11B | $1.15B | $700.70M | $1.63B | $1.49B | $958.10M | $905.00M | $1.52B | $1.76B | $1.04B | $831.20M |
| QoQ Change | — | -51.6% | +37.8% | -57.6% | -9.2% | +56.7% | -12.3% | -35.2% | +26.2% | +2.6% | +3.3% | -38.9% | +132.4% | -8.3% | -35.8% | -5.5% | +67.8% | +16.1% | -40.8% | -20.4% |
| YoY Change | — | — | — | — | -74.3% | -16.9% | -47.1% | -19.1% | +12.4% | -26.4% | -13.4% | -18.3% | +50.3% | +34.4% | -16.5% | +29.2% | -6.7% | +18.1% | +8.9% | -8.2% |
Range$700.70M – $3.75B
CAGR-27.2%
Avg YoY Growth-5.8%
Median YoY Growth-10.8%
Current Streak2 quarters decline
Pre-Tax Income at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's pre-tax income?
- Regeneron Pharmaceuticals (REGN) reported pre-tax income of $831.20M in Q1 2026.
- How has Regeneron Pharmaceuticals's pre-tax income changed year-over-year?
- Regeneron Pharmaceuticals's pre-tax income decreased by 8.2% year-over-year, from $905.00M to $831.20M.
- What is the long-term trend for Regeneron Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's pre-tax income has grown at a -13.5% compound annual growth rate (CAGR), from $9.33B to $5.23B.
- What does pre-tax income mean?
- Total profit earned before accounting for income tax obligations.